A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers | NYU Langone Health

Go Back to All Clinical Trials

A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Colorectal Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Histologically or cytologically confirmed previously treated metastatic colorectal cancer with adenocarcinoma histology. 2) Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression.

You may not be eligible for this study if the following are true:

1) BRAF V600 mutant colorectal cancer. 2) Active brain metastases or leptomeningeal metastases. 3) Active, known or suspected autoimmune disease.